# Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

> **NCT03007992** · PHASE2 · COMPLETED · sponsor: **Johannes Gutenberg University Mainz** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT03007992
- **Lead sponsor:** Johannes Gutenberg University Mainz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2019-03-02
- **Final completion:** 2019-03-02
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03007992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03007992, "Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03007992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*